Cargando…

Challenges of transferring rural adults with chronic HCV infection for further HCV RNA confirmation and free DAAs treatment: a success story of the interdisciplinary collaboration approach

BACKGROUND: Chronic hepatitis C virus (HCV), which is a concern in many countries, is the leading cause of liver cancer around the world. Since Taiwan launched its national health insurance system in 1995, it has managed to extend health coverage to 99% of the Taiwanese population, providing free bu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wei, Chang, Te-Sheng, Chang, Shu-Zhi, Chen, Ching-Hwa, Chen, Mei-Yen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542903/ https://www.ncbi.nlm.nih.gov/pubmed/33028228 http://dx.doi.org/10.1186/s12879-020-05435-3

Ejemplares similares

Efficacy and tolerability of DAAs in HCV-monoinfected and HCV/HIV-coinfected patients with psychiatric disorders
por: de Gennaro, Nicolò, et al.
Publicado: (2020)

HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
por: Chehl, Navdeep, et al.
Publicado: (2019)

Survival of HIV/HCV co-infected patients before introduction of HCV direct acting antivirals (DAA)
por: Dold, L., et al.
Publicado: (2019)

Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs
por: Paolucci, Stefania, et al.
Publicado: (2017)

Treatment and re-treatment results of HCV patients in the DAA era
por: Piecha, Felix, et al.
Publicado: (2020)

Persistence of Cryoglobulinemic Vasculitis after DAA Induced HCV Cure
por: Danishwar, Mahmood, et al.
Publicado: (2022)

Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects
por: Zuccalà, Paola, et al.
Publicado: (2022)

HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection: implications for improved diagnostic option in an era of affordable DAAs
por: Wasitthankasem, Rujipat, et al.
Publicado: (2017)

Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients
por: Maughan, A., et al.
Publicado: (2019)

Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
por: Casey, Julia L., et al.
Publicado: (2019)

Updated View on Kidney Transplant from HCV-Infected Donors and DAAs
por: Fabrizi, Fabrizio, et al.
Publicado: (2021)

Gamma-Delta T-Cell Phenotype and Function in DAA-Treated HIV-HCV Co-Infected and HCV-Mono-Infected Subjects
por: Bono, Valeria, et al.
Publicado: (2022)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update
por: Roguljic, Hrvoje, et al.
Publicado: (2021)

Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients
por: Zhang, Yu, et al.
Publicado: (2016)

Immunological and Clinical Impact of DAA-Mediated HCV Eradication in a Cohort of HIV/HCV Coinfected Patients: Monocentric Italian Experience
por: Marino, Andrea, et al.
Publicado: (2021)

Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data
por: Chen, Zhi-wei, et al.
Publicado: (2016)

Modifications of liver stiffness and CXCL4, TGF-β1 and HGF are similar in HCV- and HIV/HCV-infected patients after DAAs
por: Márquez-Coello, Mercedes, et al.
Publicado: (2021)

Oral Zinc Supplementation Decreases the Risk of HCC Development in Patients With HCV Eradicated by DAA
por: Hosui, Atsushi, et al.
Publicado: (2021)

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs
por: Minosse, Claudia, et al.
Publicado: (2021)

Longitudinal assessment of HCV core antigen kinetics to monitor therapeutic response in the age of DAAs
por: Ponnuvel, Suresh, et al.
Publicado: (2023)

Short- and Long-Term Immunological Responses in Chronic HCV/HIV Co-Infected Compared to HCV Mono-Infected Patients after DAA Therapy
por: Farcomeni, Stefania, et al.
Publicado: (2021)

DAA Treatment Failure in a HIV/HBV/HCV Co-Infected Patient Carrying a Chimeric HCV Genotype 4/1b
por: De Francesco, Maria Antonia, et al.
Publicado: (2022)

Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
por: Grottenthaler, Julia M., et al.
Publicado: (2018)

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era
por: Sacks‐Davis, Rachel, et al.
Publicado: (2018)

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC
por: Gao, Xiuzhu, et al.
Publicado: (2020)

Different Kinetics of HBV-DNA and HBsAg in HCV Coinfected Patients during DAAs Therapy
por: Colombatto, Piero, et al.
Publicado: (2022)

HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy
por: Álvarez, Beatriz, et al.
Publicado: (2022)

Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients
por: Dawood, Reham M., et al.
Publicado: (2022)

Perceptions Towards HCV Treatment with Direct Acting Antivirals (DAAs): A Qualitative Analysis with Persons with HIV/HCV Co-infection Who Delay or Refuse Treatment
por: Brothers, Sarah, et al.
Publicado: (2022)

APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
por: Kanda, Tatsuo, et al.
Publicado: (2019)

Dynamics of APRI and FIB-4 in HCV cirrhotic patients who achieved SVR after DAA therapy
por: Leuştean, Anca, et al.
Publicado: (2021)

Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV
por: Morsica, Giulia, et al.
Publicado: (2022)

Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV)
por: Walker, David R., et al.
Publicado: (2015)

Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy
por: Burchill, Matthew A., et al.
Publicado: (2017)

Retreatment of Chronic HCV Infection after Second Generation DAA Failure in Patients in the NJ VA Healthcare System
por: Stawarz, Kimberly, et al.
Publicado: (2017)

Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfected patients
por: Salmon, Dominique, et al.
Publicado: (2018)

Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST‐HCV cohort
por: Calvaruso, Vincenza, et al.
Publicado: (2021)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021)

Significant early and long-term improvement of neuropsychiatry symptomatology in HCV-infected patients after viral eradication with DAA
por: Martin-Santos, R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k5fk3fta97kv35ff39k4i1ddbb